Cell Pathways to Present at UBS Warburg Global Specialty Pharmaceuticals Conference.

Business Editors & Health/Medical Writers

UBS Warburg Global Specialty Pharmaceuticals Conference

BIOWIRE2K

HORSHAM, Pa.--(BW HealthWire)--June 4, 2002

Cell Pathways, Inc. (Nasdaq:CLPA) announced today that the company's Chairman and Chief Executive Officer, Robert J. Towarnicki, and Chief Scientific Officer, Rifat Pamukcu, M.D., will present an overview of the company's strategic plans and recent highlights at the UBS Warburg Global Specialty Pharmaceuticals Conference at the Grand Hyatt in New York City. Mr. Towarnicki's presentation will take place on Thursday, June 6th at 8:00 a.m.

Commenting on his upcoming participation in the conference, Robert J. Towarnicki stated, "In recent weeks, Cell Pathways has presented clinical data at a number of major medical meetings. Presenting at the UBS Warburg Specialty Pharmaceuticals Sciences Conference provides the opportunity to highlight that data and report the progress of our clinical development program before an audience of institutional investors who specialize in life sciences."

The presentation will be available as a live audio webcast at http://webcast.mediaondemand.com/ubs/20020605. A replay will be available 24 hours after the actual presentation time, and can be accessed at Cell Pathways' Investor Relations web site via the following link: http://webcast.mediaondemand.com/ubs/20020605. The webcast will be archived for 30 days.

Cell Pathways, Inc., headquartered in Horsham, Pennsylvania, is a development stage pharmaceutical company focused on the research and development of novel and unique medications to treat and prevent cancer and to treat certain inflammatory diseases. The company additionally markets and sells oncology-related products made by others. The company's initial drug candidates in clinical development are Aptosyn(R) (exisulind) and CP461. For additional information on Cell Pathways, Inc., visit the Company's web site at http://www.cellpathways.com.

Certain statements made herein, and oral statements made in respect hereof, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are those, which express plan, anticipation, intent, contingency or future development and/or otherwise are not statements of historical fact. These statements are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These risks are detailed in the Company's reports filed from time to time under the Securities Act of 1933 and/or the Securities Exchange Act of 1934. You are encouraged to read these filings as they are made. They are available over the Internet from the SEC in its EDGAR database. Investors are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. No forward-looking statement can be guaranteed; actual future results may vary materially. Both forward-looking statements and statements of historic fact must be understood in the context of the risks referred to above which characterize the Company's development stage business. The Company undertakes no obligation to update or revise the statements made herein or the factors, which may relate thereto.